Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NUDT1 | P36639 | 1/20 | 0.47 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.47 |
| ▸ | NPY5R | Q15761 | 3/20 | 0.46 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.46 |
| ▸ | CDK2 | P24941 | 1/20 | 0.46 |
| ▸ | AKT2 | P31751 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CRHBP | P24387 | 1/20 | 0.41 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MAP2K7 | O14733 | 2/20 | 0.40 |
| ▸ | NOS1 | P29475 | 2/20 | 0.39 |
| ▸ | CHUK | O15111 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cadaverine Tartrate SCHEMBL30640520 | 0.87 | NPY5R (0.40) | NUDT1HRH4NPY5RCCNA2CDK2 | |
| Cadaverine Tartrate SCHEMBL26673711 | 0.87 | NPY5R (0.40) | NUDT1HRH4NPY5RCCNA2CDK2 | |
| SCHEMBL2634662 | 0.70 | NUDT1 (0.61) | NUDT1CCNA2CDK2 | |
| SCHEMBL1290911 | 0.70 | NUDT1 (0.61) | NUDT1CCNA2CDK2AKT2LMNA | |
| SCHEMBL17822430 | 0.69 | LMNA (0.55) | NPY5RLMNACRHBPCRHR2SMN1; SMN2 | |
| SCHEMBL17822445 | 0.69 | LMNA (0.55) | NPY5RLMNACRHBPCRHR2SMN1; SMN2 | |
| SCHEMBL17979711 | 0.69 | CHRM3 (0.49) | NUDT1LMNACRHBPCRHR2SMN1; SMN2 | |
| SCHEMBL2776067 | 0.69 | NUDT1 (0.46) | NUDT1HRH4CRHBPCRHR2MAP2K7 | |
| Hydrochloric Acid SCHEMBL8582393 | 0.69 | NPY5R (0.47) | HRH4NPY5RAKT2 | |
| SCHEMBL31419879 | 0.68 | LMNA (0.53) | LMNACRHBPCRHR2SMN1; SMN2NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260049083-A1 | DEUTERIUM-ENRICHED PIPERIDINYL-METHYL-PURINE AMINES AND RELATED COMPOUNDS AND THEIR USE IN TREATING DISEASES AND CONDITIONS | K36 THERAPEUTICS INC (US) | 2026-02-19 | — | — | US | disclosed |
| WO-2025259850-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING A DEUTERIUM-ENRICHED PIPERIDINYL-METHYL-PURINE AMINE AND THEIR USE IN TREATING DISEASES AND CONDITIONS | K36 THERAPEUTICS, INC. (US) | 2025-12-18 | — | — | WO | disclosed |
| US-12492203-B2 | Deuterium-enriched piperidinyl-methyl-purine amines and related compounds and their use in treating diseases and conditions | K36 THERAPEUTICS, INC. (US) | 2025-12-09 | — | — | US | disclosed |
| US-20250326752-A1 | PIPERIDINYL-METHYL-PURINE AMINE SALTS, CRYSTALLINE FORMS, AND THEIR USE IN TREATING MEDICAL DISEASES AND CONDITIONS | K36 THERAPEUTICS INC (US) | 2025-10-23 | — | — | US | disclosed |
| US-20250326752-A1 | PIPERIDINYL-METHYL-PURINE AMINE SALTS, CRYSTALLINE FORMS, AND THEIR USE IN TREATING MEDICAL DISEASES AND CONDITIONS | K36 THERAPEUTICS INC (US) | 2025-10-23 | — | — | US | disclosed |
| US-20250326752-A1 | PIPERIDINYL-METHYL-PURINE AMINE SALTS, CRYSTALLINE FORMS, AND THEIR USE IN TREATING MEDICAL DISEASES AND CONDITIONS | K36 THERAPEUTICS INC (US) | 2025-10-23 | — | — | US | disclosed |
| EP-4633637-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING A PIPERIDINYL-METHYL-PURINE AMINE AND THEIR USE IN TREATING DISEASES AND CONDITIONS | K36 Therapeutics, Inc. (US) | 2025-10-22 | — | — | EP | disclosed |
| WO-2025147514-A1 | PIPERIDINYL-METHYL-PURINEAMINE NSD2 INHIBITOR THERAPEUTIC METHODS AND COMPOSITIONS FOR TREATING CANCER | K36 THERAPEUTICS, INC. (US) | 2025-07-10 | — | — | WO | disclosed |
| CN-120192320-A | Pyridinylpiperidine compounds, and preparation method and application thereof | 上海交通大学 | 2025-06-24 | — | — | CN | disclosed |
| US-20250171445-A1 | DEUTERIUM-ENRICHED PIPERIDINYL-METHYL-PURINE AMINE SALTS, CRYSTALLINE FORMS, AND THEIR USE IN TREATING MEDICAL DISEASES AND CONDITIONS | K36 THERAPEUTICS, INC. | 2025-05-29 | — | — | US | disclosed |
| WO-2023225144-A1 | PIPERIDINYL-METHYL-PURINE AMINE SALTS, CRYSTALLINE FORMS, AND THEIR USE IN TREATING MEDICAL DISEASES AND CONDITIONS | K36 THERAPEUTICS, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023225144-A1 | PIPERIDINYL-METHYL-PURINE AMINE SALTS, CRYSTALLINE FORMS, AND THEIR USE IN TREATING MEDICAL DISEASES AND CONDITIONS | K36 THERAPEUTICS, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023225144-A1 | PIPERIDINYL-METHYL-PURINE AMINE SALTS, CRYSTALLINE FORMS, AND THEIR USE IN TREATING MEDICAL DISEASES AND CONDITIONS | K36 THERAPEUTICS, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023225150-A1 | PIPERIDINYL-METHYL-PURINE AMINE FUMARIC ACID SALTS, CRYSTALLINE FORMS, AND THEIR USE IN TREATING MEDICAL DISEASES AND CONDITIONS | K36 THERAPEUTICS, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023225150-A1 | PIPERIDINYL-METHYL-PURINE AMINE FUMARIC ACID SALTS, CRYSTALLINE FORMS, AND THEIR USE IN TREATING MEDICAL DISEASES AND CONDITIONS | K36 THERAPEUTICS, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023225154-A1 | PIPERIDINYL-METHYL-PURINE AMINE SALTS, CRYSTALLINE FORMS, AND THEIR USE IN TREATING MEDICAL DISEASES AND CONDITIONS | K36 THERAPEUTICS, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023133201-A1 | DEUTERIUM-ENRICHED PIPERIDINYL-METHYL-PURINE AMINES AND RELATED COMPOUNDS AND THEIR USE IN TREATING DISEASES AND CONDITIONS | K36 THERAPEUTICS, INC. (US) | 2023-07-13 | — | — | WO | disclosed |
| EP-4013755-A1 | PIPERIDINYL-METHYL-PURINEAMINES AS NSD2 INHIBITORS AND ANTI-CANCER AGENTS | Novartis AG (CH) | 2022-06-22 | — | — | EP | disclosed |
| CN-114585622-A | Piperidinyl-methyl-purinamines as NSD2 inhibitors and anticancer agents | 诺华股份有限公司 | 2022-06-03 | — | — | CN | disclosed |
| CN-114585622-A | Piperidinyl-methyl-purinamines as NSD2 inhibitors and anticancer agents | 诺华股份有限公司 | 2022-06-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250326752-A1 | PIPERIDINYL-METHYL-PURINE AMINE SALTS, CRYSTALLINE FORMS, AND THEIR USE IN TREATING MEDICAL DISEASES AND CONDITIONS | AMPD2, NSD2, PNP | NUDT1 6/4885HRH4 1991/4885NPY5R 3668/4885 |
| US-20250171445-A1 | DEUTERIUM-ENRICHED PIPERIDINYL-METHYL-PURINE AMINE SALTS, CRYSTALLINE FORMS, AND THEIR USE IN TREATING MEDICAL DISEASES AND CONDITIONS | NSD2, AMPD2, FANCD2 | NUDT1 15/4885HRH4 1314/4885NPY5R 2130/4885 |
| US-20260049083-A1 | DEUTERIUM-ENRICHED PIPERIDINYL-METHYL-PURINE AMINES AND RELATED COMPOUNDS AND THEIR USE IN TREATING DISEASES AND CONDITIONS | NSD2, NSD1, NSD3 | NUDT1 131/4885HRH4 326/4885NPY5R 1169/4885 |
| US-12492203-B2 | Deuterium-enriched piperidinyl-methyl-purine amines and related compounds and their use in treating diseases and conditions | NSD2, NSD1, NSD3 | NUDT1 24/4885HRH4 1343/4885NPY5R 2736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.